Delving into the Latest Updates on BMS-986326 with Synapse

Overview

Basic Info

Drug Type

Fusion protein

Synonyms

IL-2/CD25(Bristol-Myers Squibb)

Target

IL-2R x IL2RA

Action

modulators, inhibitors

Mechanism

IL-2R modulators(Interleukin-2 receptor modulators), IL2RA inhibitors(Interleukin-2 receptor alpha chain inhibitors)

Therapeutic Areas

Immune System DiseasesCongenital DisordersSkin and Musculoskeletal Diseases+ [1]

Active Indication

Dermatitis, AtopicLupus Erythematosus, DiscoidSystemic Lupus Erythematosus+ [1]

Inactive Indication-

Originator Organization

Bristol Myers Squibb Co.

Active Organization

Bristol Myers Squibb Co.

University of Miami

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

AbstractLow-dose IL-2 represents an immunotherapy to selectively expand regulatory T cells (Tregs) to promote tolerance in patients with autoimmunity. In this article, we show that a fusion protein (FP) of mouse IL-2 and mouse IL-2Rα (CD25), joined by a noncleavable linker, has greater in vivo efficacy than rIL-2 at Treg expansion and control of autoimmunity. Biochemical and functional studies support a model in which IL-2 interacts with CD25 in the context of this FP in trans to form inactive head-to-tail dimers that slowly dissociate into an active monomer. In vitro, IL-2/CD25 has low sp. act. However, in vivo IL-2/CD25 is long lived to persistently and selectively stimulate Tregs. In female NOD mice, IL-2/CD25 administration increased Tregs within the pancreas and reduced the instance of spontaneous diabetes. Thus, IL-2/CD25 represents a distinct class of IL-2 FPs with the potential for clinical development for use in autoimmunity or other disorders of an overactive immune response.

100 Deals associated with BMS-986326

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lupus Erythematosus, Discoid	Phase 1	Romania	Bristol Myers Squibb Co.	21 Sep 2023
Lupus Erythematosus, Discoid	Phase 1	United States	Bristol Myers Squibb Co.	21 Sep 2023
Lupus Erythematosus, Discoid	Phase 1	Bulgaria	Bristol Myers Squibb Co.	21 Sep 2023
Lupus Erythematosus, Discoid	Phase 1	Poland	Bristol Myers Squibb Co.	21 Sep 2023
Lupus Erythematosus, Discoid	Phase 1	Argentina	Bristol Myers Squibb Co.	21 Sep 2023
Lupus Erythematosus, Discoid	Phase 1	Spain	Bristol Myers Squibb Co.	21 Sep 2023
Lupus Erythematosus, Discoid	Phase 1	Mexico	Bristol Myers Squibb Co.	21 Sep 2023
Lupus Erythematosus, Discoid	Phase 1	Germany	Bristol Myers Squibb Co.	21 Sep 2023
Systemic Lupus Erythematosus	Phase 1	Bulgaria	Bristol Myers Squibb Co.	21 Sep 2023
Systemic Lupus Erythematosus	Phase 1	Germany	Bristol Myers Squibb Co.	21 Sep 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04736134 (BMS-986326, EADV2023)	Phase 1	Treg IL-2 receptor \| phosphorylated STAT5 \| CD25	32	BMS-986326	glfoogtmmk(qjuhtkayoi) = zivxkpsnxe itogyumdya (pfahhdryei )	Positive	11 Oct 2023

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data